CABANA trial: “beauty is in the eye of the beholder”

David Briceno; Prasant Mohanty; Luigi Di Biase; Jorge Romero; Domenico Giovanni Della Rocca; Chintan Trivedi; Sanghamitra Mohanty; Andrea Natale

doi:10.1007/s10840-019-00604-0

CABANA trial: “beauty is in the eye of the beholder”

David Briceno, Prasant Mohanty, Luigi Di Biase, Jorge Romero, Domenico Giovanni Della Rocca, Chintan Trivedi, Sanghamitra Mohanty, Andrea Natale

Medicine

Research output: Contribution to journal › Comment/debate

Abstract

The CABANA trial reported that catheter ablation, when compared with drug therapy, did not significantly reduce the primary composite end point of death, disabling stroke, serious bleeding, or cardiac arrest in patients with atrial fibrillation. Despite multiple limitations in study design, the CABANA trial still confirmed that catheter ablation of atrial fibrillation led to clinically important and significant improvements in quality of life at 12 months without increasing the risk of complications.

Original language	English (US)
Journal	Journal of Interventional Cardiac Electrophysiology
Volume	57
Issue number	1
DOIs	https://doi.org/10.1007/s10840-019-00604-0
State	Published - Jan 1 2020

Keywords

Ablation
Atrila fibrillation
Mortality
Outcomes

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Physiology (medical)

Access to Document

10.1007/s10840-019-00604-0

Fingerprint Dive into the research topics of 'CABANA trial: “beauty is in the eye of the beholder”'. Together they form a unique fingerprint.

Cite this

Briceno, D., Mohanty, P., Di Biase, L., Romero, J., Rocca, D. G. D., Trivedi, C., Mohanty, S., & Natale, A. (2020). CABANA trial: “beauty is in the eye of the beholder”. Journal of Interventional Cardiac Electrophysiology, 57(1). https://doi.org/10.1007/s10840-019-00604-0

@article{ea202f9f3eb04ce8a042835d413a899c,

title = "CABANA trial: “beauty is in the eye of the beholder”",

abstract = "The CABANA trial reported that catheter ablation, when compared with drug therapy, did not significantly reduce the primary composite end point of death, disabling stroke, serious bleeding, or cardiac arrest in patients with atrial fibrillation. Despite multiple limitations in study design, the CABANA trial still confirmed that catheter ablation of atrial fibrillation led to clinically important and significant improvements in quality of life at 12 months without increasing the risk of complications.",

keywords = "Ablation, Atrila fibrillation, Mortality, Outcomes",

author = "David Briceno and Prasant Mohanty and {Di Biase}, Luigi and Jorge Romero and Rocca, {Domenico Giovanni Della} and Chintan Trivedi and Sanghamitra Mohanty and Andrea Natale",

year = "2020",

month = jan,

day = "1",

doi = "10.1007/s10840-019-00604-0",

language = "English (US)",

volume = "57",

journal = "Journal of Interventional Cardiac Electrophysiology",

issn = "1383-875X",

publisher = "Springer Netherlands",

number = "1",

}

TY - JOUR

T1 - CABANA trial

T2 - “beauty is in the eye of the beholder”

AU - Briceno, David

AU - Mohanty, Prasant

AU - Di Biase, Luigi

AU - Romero, Jorge

AU - Rocca, Domenico Giovanni Della

AU - Trivedi, Chintan

AU - Mohanty, Sanghamitra

AU - Natale, Andrea

PY - 2020/1/1

Y1 - 2020/1/1

N2 - The CABANA trial reported that catheter ablation, when compared with drug therapy, did not significantly reduce the primary composite end point of death, disabling stroke, serious bleeding, or cardiac arrest in patients with atrial fibrillation. Despite multiple limitations in study design, the CABANA trial still confirmed that catheter ablation of atrial fibrillation led to clinically important and significant improvements in quality of life at 12 months without increasing the risk of complications.

AB - The CABANA trial reported that catheter ablation, when compared with drug therapy, did not significantly reduce the primary composite end point of death, disabling stroke, serious bleeding, or cardiac arrest in patients with atrial fibrillation. Despite multiple limitations in study design, the CABANA trial still confirmed that catheter ablation of atrial fibrillation led to clinically important and significant improvements in quality of life at 12 months without increasing the risk of complications.

KW - Ablation

KW - Atrila fibrillation

KW - Mortality

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=85071752613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071752613&partnerID=8YFLogxK

U2 - 10.1007/s10840-019-00604-0

DO - 10.1007/s10840-019-00604-0

M3 - Comment/debate

C2 - 31493123

AN - SCOPUS:85071752613

VL - 57

JO - Journal of Interventional Cardiac Electrophysiology

JF - Journal of Interventional Cardiac Electrophysiology

SN - 1383-875X

IS - 1

ER -